Search Results

Skinvisible Pharmaceuticals, Inc., an innovative pharmaceutical research and development company, announced a major advancement in the battle against obesity.

Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an innovative topical / transdermal pharmaceutical research and development company, today announced the filing of a second patent application for its groundbreaking Invisicare® technology and its transdermal delivery of obesity and glucose-controlling agents.

Skinvisible, Inc. (“Skinvisible”) (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin Pharmaceuticals, Inc. (“Quoin”) (NASDAQ:QNRX).

Skinvisible, Inc., is pleased to announce that its licensee Quoin Pharmaceuticals, Inc., has received U.S. FDA acceptance of its Investigational New Drug application for its licensed formulation which uses Skinvisible’s Invisicare® proprietary drug delivery technology.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).